High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer

Current Cancer Drug Targets

Volumn 12, Issue 6, 2012, Pages 693-702

  D'Alterio, C ^a   Portella, L ^a   Ottaiano, A ^a   Rizzo, M ^b   Carteni G ^b   Pignata, S ^a   Facchini, G ^a   Perdona S ^a   Di Lorenzo, G ^c   Autorino, R ^a   Franco, R ^a   la Mura, A ^b   Nappi, O ^b   Castello, G ^a   Scala, S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

CCR4; First line therapy; mRCC; Response to therapy; Sunitinib; Survival analyses

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; SUNITINIB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG RESPONSE; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; ITALY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PYRROLES; RECEPTORS, CXCR4; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862619467     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912801784820     Document Type: Article

References (45)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Motzer, R. J.; Bukowski, R. M.: Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24, 5601-5608.
3. Staller, P.; Sulitkova, J.; Lisztwan, J.; Moch, H.; Oakeley, E. J.; Krek, W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425, 307-311.
4. Zagzag, D.; Krishnamachary, B.; Yee, H.; Okuyama, H.; Chiriboga, L.; Ali, M.A.; Melamed, J.; Semenza, G. L. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel- Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 2005, 65, 6178-6188.
5. Di Lorenzo, G.; Buonerba, C.; Federico, P.; Rescigno, P.; Milella, M.; Ortega, C.; Aieta, M.; D'Aniello, C.; Longo, N.; Felici, A.; Ruggeri, E. M.; Palmieri, G.; Imbimbo, C.; Aglietta, M.; De Placido, S.; Mirone, V. Third-line sorafenib after sequential therapy with sunitinib and mtor inhibitors in metastatic renal cell carcinoma. Eur. Urol. 2010, 58 (6), 906-911.
6. Thompson, C. J.; Hoyle, M.; Green, C.; Liu, Z.; Welch, K.; Moxham, T.; Stein, K. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol. Assess. 2010, 14, 1-184.
7. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T.; Chen, I.; Bycott, P. W.; Baum, C. M.; Figlin, R. A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 115-124.
8. Motzer, R. J.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Figlin R. A.; Ginsberg, M. S.; Kim, S. T.; Baum, C. M.; De Primo, S. E.; Li, J. Z.; Bello, C. L.; Theuer, C. P.; George, D. J.; Rini, B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24, 16-24.
9. Di Fiore, F.; Rigal, O.; Ménager, C.; Michel, P.; Pfister, C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br. J. Cancer 2011, 105 (12), 1811-1813.
10. Karakiewicz, P. I.; Briganti, A.; Chun, F. K.; Trinh, Q. D.; Perrotte, P.; Ficarra, V.; Cindolo, L.; De la Taille, A.; Tostain, J.; Mulders, P. F.; Salomon, L.; Zigeuner, R.; Prayer-Galetti, T.; Chautard, D.; Valeri, A.; Lechevallier, E.; Descotes, J. L.; Lang, H.; Mejean, A.; Patard, J. J. Multi-institutional validation of a new renal cancerspecific survival nomogram. J. Clin. Oncol. 2007, 25, 1316-1322.
11. Isbarn, H.; Karakiewicz, P. I. Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr. Opin. Urol. 2009, 19, 247-257.
12. Garcia-Donas, J.; Esteban, E.; Leandro-García, L. J.; Castellano, D. E.; del Alba, A. G.; Climent, M. A.; Arranz, J. A.; Gallardo, E.; Puente, J.; Bellmunt, J.; Mellado, B.; Martínez, E.; Moreno, F.; Font, A.; Robledo, M.; Rodríguez-Antona, C. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011, 12 (12), 1143-1150.
13. Brower, V. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J. Natl. Cancer Inst. 2009, 101, 846-847.
14. Kontovinis, L. F.; Papazisis, K. T.; Touplikioti, P.; Andreadis, C.; Mouratidou, D.; Kortsaris, A. H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 12, 9, 82.
15. Kopetz, S.; Hoff, P. M.; Morris, J. S.; Wolff, R. A.; Eng, C.; Glover, K. Y.; Adinin, R.; Overman, M. J.; Valero, V.; Wen, S.; Lieu, C.; Yan, S.; Tran, H. T.; Ellis L. M.; Abbruzzese, J. L.; Heymach, J. V. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28, 453-459.
16. Perez-Gracia, J. L.; Prior, C.; Guillén-Grima, F.; Guillén-Grima, F.; Segura, V.; Gonzalez, A.; Panizo, A.; Melero, I.; Grande-Pulido, E.; Gurpide, A.; Gil-Bazo, I.; Calvo, A. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br. J. Cancer 2009, 101, 1876-1883.
17. Porta, C. Regarding 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'. Br. J. Cancer 2010, 102, 1196-1197.
18. Porta, C.; Paglino, C.; De Amici, M.; Quaglini, S.; Sacchi, L.; Imarisio, I.; Canipari, C. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinaseassociated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010, 77, 809-815.
19. Gossage, L.; Eisen, T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat. Rev. Clin. Oncol. 2010, 7, 277-288.
20. D'Alterio, C.; Consales, C.; Polimeno, M., Franco, R.; Cindolo, L.; Portella, L.; Cioffi, M.; Calemma, R.; Cartenì, G.; Longo, N.; Pucci, L.; Marra, L.; Claudio, L.; Perdonà, S.; Pignata, S.; Facchini, G.; Ottaiano, A.; Costantini, S.; Castello, G.; Scala, S. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr. Cancer Drug Target 2010, 10, 772-781.
21. D'Alterio, C.; Cindolo, L.; Portella, L.; Polimeno, M.; Consales, C.; Riccio, A.; Cioffi M.; Franco, R.; Chiodini, P.; Cartenì, G.; Mirone, V.; Longo, N.; Marra, L.; Perdonà, S.; Claudio, L.; Mascolo, M.; Staibano, S.; Falsaperla, M.; Puglisi, M.; Martignoni, G.; Ficarra, V.; Castello, G.; Scala, S. Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010, 9, 4492-4500.
22. Ruffini, P. A.; Morandi, P.; Cabioglu, N.; Altundag, K.; Cristofanilli, M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007, 109, 2392-2404.
23. Ottaiano, A.; Franco, R.; Aiello Talamanca, A.; Liguori, G.; Tatangelo, F.; Delrio, P.; Falanga, M.; Boccia, V.; Capuozzo, M.; Parisi, V.; Botti, G.; Castello, G.; Iaffaioli, V.; Scala, S. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res. 2006, 12, 2795-2803.
24. Xiang, Z.; Zeng, Z.; Tang, Z.; Fan, J.; Sun, H.; Wu, W.; Tan, Y. Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. Cancer J. 2009, 15, 519-525.
25. Xu, L.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Chung, D. C.; Lauwers, G. Y.; Samuel, R.; Shellito, P.; Czito, B. G.; Lin, P. C.; Poleski, M.; Bentley, R.; Clark, J. W.; Willett, C. G.; Jain, R. K. Direct evidence that bevacizumab, an anti-VEGF antibody, upregulates CXCL12, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009, 69, 7905-7910.
26. Batchelor, T. T.; Sorensen, A. G.; di Tomaso, E.; Zhang, W. T.; Duda, D. G.; Cohen, K. S.; Kozak, K. R.; Cahill, D. P.; Chen, P. J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M. M.; Plotkin, S.; Drappatz, J.; Louis, D. N.; Ivy, P.; Scadden, D. T.; Benner, T.; Loeffler, J. S.; Wen, P. Y.; Jain, R. K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007, 11, 83-95.
27. Zhu, A. X.; Sahani, D. V.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O. A.; Sindhwani, V.; Blaszkowsky, L. S.; Yoon, S. S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J. W.; Kwak E. L.; Hezel, A. F.; Miksad, R.; Abrams, T. A.; Enzinger, P. C.; Fuchs, C. S.; Ryan, D. P.; Jain, R. K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 27, 3027-3035.
28. Therasse, P.; Arbuck S. G.;, Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubistein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000, 92, 205-216
29. Motzer, R. J.; Bacik, J.; Murphy, B. A.; Russo P.; Mazumdar, M. Interferon alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002, 20, 289-296.
30. Heng, D. Y.; Xie, W.; Regan, M. M.; Warren, M. A.; Golshayan, A. R.; Sahi, C.; Eigl, B. J.; Ruether, J. D.; Cheng, T.; North, S.; Venner, P.; Knox, J. J.; Chi, K. N.; Kollmannsberger, C.; McDermott, D. F.; Oh, W. K.; Atkins, M. B.; Bukowski, R. M.; Rini, B. I.; Choueiri, T. K. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009, 27 (34), 5794-5799.
31. Devarajan, P. The promise of biomarkers for personalized renal cancer care. Kidney Int. 2010, 77, 755-757.
32. Dorai, T.; Sawczuk, I. S.; Pastorek, J.; Wiernik, P. H.; Dutcher, J. P. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur. J. Cancer 2005, 41, 2935-2947.
33. Atkins, M.; Regan, M.; McDermott, D.; Mier, J.; Stanbridge, E.; Youmans, A.; Febbo, P.; Upton, M.; Lechpammer, M.; Signoretti, S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 2005, 11, 3714-3721.
34. Patard, J. J.; Fergelot, P.; Karakiewicz, P. I.; Klatte, T.; Trinh, Q. D.; Rioux-Leclercq, N.; Said, J. W.; Belldegrun, A. S.; Pantuck, A. J. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer 2008, 123, 395-400.
35. Patard, J. J.; Lechevallier, E.; Descazeaud, A. Kidney cancer: news in 2008. Prog. Urol. 2008, 18 (6), 135-140.
36. Klatte, T.; Seligson, D. B.; LaRochelle, J.; Shuch, B.; Said, J.W.; Riggs, S. B.; Zomorodian, N.; Kabbinavar, F. F.; Pantuck, A. J.; Belldegrun, A. S. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-freesurvival after nephrectomy. Cancer Epidemiol. Biomarkers Prev. 2009, 18 (3), 894-900.
37. Choueiri, T. K.; Vaziri, S. A.; Jaeger, E., Elson, P.; Wood, L.; Bhalla, I. P.; Small, E. J.; Weinberg, V.; Sein, N.; Simko, J.; Golshayan, A. R.; Sercia, L.; Zhou, M.; Waldman, F. M.; Rini, B. I.; Bukowski, R. M.; Ganapathi, R. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 2008, 180, 860-865.
38. Shin, H. W.; Cho, C. H.; Kim, T. Y.; Park, J. W. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. Biochem. Biophys. Res. Commun. 2010, 398, 205-211.
39. Ebos, J. M.; Lee, C. R.; Christensen, J. G.; Mutsaers, A. J.; Kerbel, R. S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. USA 2007, 104, 17069-17074.
40. Garcia, J. A.; Cowey, C. L.; Godley, P. A. Renal cell carcinoma. Curr. Opin. Oncol. 2009, 21, 266-271.
41. Reckamp, K. L.; Strieter, R. M.; Figlin, R. A. Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev. Anticancer Ther. 2008, 8 (6), 887-893.
42. Stafford, H. S.; Saltzstein, S. L.; Shimasaki, S., Sanders, C.; Downs, T. M.; Sadler, G. R.; Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J. Urol. 2008, 179 (5), 1704-1708.
43. Woldrich, J. M.; Mallin, K.; Ritchey, J.; Carroll, P. R.; Kane, C. J. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J. Urol. 2008, 179 (5), 1709-1713.
44. Kutikov, A.; Egleston, B. L.; Wong, Y. N.; Uzzo, R. G.; Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J. Clin. Oncol. 2010, 28 (2), 311-317.
45. Rajandram, R.; Bennett, N. C.; Morais, C.; Johnson, D. W.; Gobe, G. C. Renal cell carcinoma: Resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins. Med. Hypotheses. 2012, 78 (2), 330-336.